Experimental t cell therapy targets Hard-to-Treat KRAS cancers

NCT ID NCT06546150

Recruiting now Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new treatment called RE002 T cells for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The study will enroll 30 adults who have run out of standard options. Participants first receive chemotherapy to prepare their immune system, then get the RE002 T cell infusion. The main goal is to see if the tumors shrink and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RE002 T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific KRAS mutation.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so it is not yet known if the treatment works or is safe. There are risks from the chemotherapy given beforehand and possible side effects from the T cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12D are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS G12D T CELL THERAPY

Contacts and locations

Locations

Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.